<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214587</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0, date 01-01-2020</org_study_id>
    <nct_id>NCT04214587</nct_id>
  </id_info>
  <brief_title>Biological Investigation of Explanted Endobronchial Lung Valves Study</brief_title>
  <acronym>Bio-EXCEL</acronym>
  <official_title>Biological Investigation of Explanted Endobronchial Lung Valves Study - Investigation of the Mechanism of Action of Tissue-device Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      COPD is a severe, often progressive and currently incurable lung disease which affects both
      the upper airways (chronic bronchitis) as well as the lower airways (emphysema). In advanced
      stages of the disease air-trapping severely reduces the ability to breathe and subsequently
      the quality of life. A highly effective treatment for restoring lung mechanical functionality
      of these patients is the introduction of bronchoscopic lung volume reduction (BLVR), e.g.
      implanting small silicone/nitinol valves (EBV) inside the airways to reduce air-trapping.
      Although successfully investigated in a selected group of severe COPD patients, the
      effectiveness of the treatment can sometimes be short-lived due to fibrotic and granulation
      responses and tissue-material interactions.

      Objective:

      The main objective of this study is to study and understand the underlying biological
      principles of granulation and fibrotic responses limiting the effectiveness and longevity of
      BELVR treatment with EBVs, this to investigate the mechanism of action of tissue-device
      interactions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the % of the 150 patients that will develop a need for rebronchoscopy after 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>frequency</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Emphysema or COPD</condition>
  <arm_group>
    <arm_group_label>baseline assessment group</arm_group_label>
    <description>n=150 patiënts for baseline assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clinical need for reintervention group</arm_group_label>
    <description>n=20-30 patiënts for re-bronchoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clinical stable controls</arm_group_label>
    <description>n=20 stable treated control patiënts</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>tissue and blood sampling</intervention_name>
    <description>only diagnostics will be peformed</description>
    <arm_group_label>baseline assessment group</arm_group_label>
    <arm_group_label>clinical need for reintervention group</arm_group_label>
    <arm_group_label>clinical stable controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      epithial brushings blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Severe emphysema patients routinely scheduled for bronchoscopic lung volume reduction with
        one-way endobronchial valves
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elidgible for EBV treatment

        Exclusion Criteria:

          -  Anticoagulation which cannot be stopped prior to the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC-Groningen/NL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk-Jan Slebos, MD PhD</last_name>
    <phone>+31503616161</phone>
    <email>d.j.slebos@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorine Hartman, PhD</last_name>
    <email>j.hartman@umcg.nl</email>
  </overall_contact_backup>
  <link>
    <url>http://www.bicumcg.nl</url>
    <description>The UMC-Groningen/NL Bronchoscopic Intervention Center website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dirk-Jan Slebos</investigator_full_name>
    <investigator_title>Prof. dr. D.J. Slebos MD, PhD, Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

